Boehringer/Zealand’s Obesity Asset Succeeds In Phase II But Competition Is Fierce
Pivotal Plans In The Works
The partners’ dual GLP-1/GCGR agonist has achieved up to 14.9% weight loss in obese and overweight adults in a mid-stage trial but rival products Wegovy and Mounjaro will likely dominate the space according to analysts.
You may also be interested in...
Lilly And Novo Nordisk Shape Up For Obesity Treatment Battle Of The Heavyweights
Eli Lilly’s Mounjaro looks set to gain US approval for obesity this year and upcoming Phase III data could help it eclipse the huge success of Novo Nordisk’s Wegovy.
Zealand Eyes Opportunities In Burgeoning Obesity Market
Given the renewed interest in the commercial potential of obesity therapies, Zealand is heralding the potential of its treatments for the overweight.
Novo’s Wegovy Excels But Lilly Rival Hot On Heels
After months of manufacturing blunders, the Danish major’s obesity drug has shown its blockbuster potential in the first quarter but rival Eli Lilly could soon stoke up the competition.